Third Harmonic Bio (THRD) Stock Forecast, Price Target & Predictions
THRD Stock Forecast
Third Harmonic Bio stock forecast is as follows: an average price target of $16.15 (represents a 41.05% upside from THRD’s last price of $11.45) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
THRD Price Target
THRD Analyst Ratings
Buy
Third Harmonic Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 09, 2024 | Michael Ulz | Morgan Stanley | $20.00 | $10.86 | 84.16% | 74.67% |
Jun 17, 2024 | Alex Thompson | Stifel Nicolaus | $23.00 | $12.95 | 77.61% | 100.87% |
Jun 07, 2024 | Laura Prendergast | Raymond James | $18.00 | $14.49 | 24.22% | 57.21% |
Dec 16, 2022 | - | Morgan Stanley | $5.00 | $4.27 | 17.10% | -56.33% |
Dec 16, 2022 | - | Jefferies | $3.60 | $4.30 | -16.28% | -68.56% |
10
Third Harmonic Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 3 |
Avg Price Target | - | - | $20.33 |
Last Closing Price | $11.45 | $11.45 | $11.45 |
Upside/Downside | -100.00% | -100.00% | 77.55% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 08, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
Jun 06, 2024 | Raymond James | - | Outperform | Initialise |
Dec 16, 2022 | Morgan Stanley | - | Equal-Weight | Downgrade |
10
Third Harmonic Bio Financial Forecast
Third Harmonic Bio Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Third Harmonic Bio EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Third Harmonic Bio Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-15.08M | $-13.43M | $-13.43M | $-14.46M | $-15.11M | $-12.36M | $-11.64M |
High Forecast | $-15.08M | $-13.43M | $-13.43M | $-14.46M | $-13.52M | $-12.36M | $-11.64M |
Low Forecast | $-15.08M | $-13.43M | $-13.43M | $-14.46M | $-17.10M | $-12.36M | $-11.64M |
Surprise % | - | - | - | - | - | - | - |
Forecast
Third Harmonic Bio SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Forecast
Third Harmonic Bio EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.36 | $-0.33 | $-0.33 | $-0.35 | $-0.37 | $-0.30 | $-0.29 |
High Forecast | $-0.36 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.30 | $-0.29 |
Low Forecast | $-0.36 | $-0.33 | $-0.33 | $-0.35 | $-0.41 | $-0.30 | $-0.29 |
Surprise % | - | - | - | - | - | - | - |
Forecast
Third Harmonic Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
PASG | Passage Bio | $0.54 | $6.00 | 1011.11% | Buy |
HOWL | Werewolf Therapeutics | $1.78 | $12.00 | 574.16% | Buy |
ACRV | Acrivon Therapeutics | $6.44 | $21.83 | 238.98% | Buy |
CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
NXTC | NextCure | $1.29 | $3.00 | 132.56% | Buy |
THRD | Third Harmonic Bio | $11.45 | $16.15 | 41.05% | Buy |
EWTX | Edgewise Therapeutics | $31.98 | $45.00 | 40.71% | Buy |
GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
RVMD | Revolution Medicines, Inc. Warrant | $56.78 | $60.63 | 6.78% | Buy |